Hassan Kanj
Piscataway, NJNPI 1598815987
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,969 of the $108,855 with a category attached, or 82.7%. 49 manufacturers reported payments, led by Novo Nordisk at 58.6% of the total. Reporting peaked in 2019 at $41,730 and has fallen 99.8% since, to $102 in 2025.
Across 1,066 payments — averaging $102.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$64K
- AstraZeneca$28K
- Amarin Pharma, Inc.$6K
- Johnson & Johnson$2K
- Sanofi-aventis U.S. LLC$1K
- Abbott$812
- plus $7K from 43 others
What the payments were for
- Speaking & faculty fees$89,96983%
- Travel & lodging$1,8082%
- Food & beverage$17,06216%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 117 | $203,114 |
| FarxigaDapagliflozin Propanediol | 58 | $55,717 |
| JardianceEmpagliflozin | 52 | $51,885 |
| JanuviaSitagliptin Phosphate | 38 | $42,103 |
| ProliaDenosumab | 11 | $18,528 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $16,106 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $10,137 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $8,672 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $8,403 |
| Humalog Mix 50-50 KwikpenInsulin Lispro Protamin/Lispro | 12 | $3,706 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 29 | $3,544 |
| Repaglinide | 68 | $2,148 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,543 |
| Levothyroxine Sodium | 115 | $1,141 |
| Metformin Hcl ErMetformin Hcl | 83 | $1,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $63,793 | $203,114117 claims |
| AstraZenecaFarxiga | $28,334 | $55,71758 claims |
| Boehringer IngelheimJardiance | $428 | $51,88552 claims |
| MerckJanuvia | $678 | $42,10338 claims |
| AmgenProlia | $111 | $18,52811 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $629 | $1,141115 claims |
| AbbVieSynthroid | $443 | $70316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.